MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback (MOVES)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03820024 |
Recruitment Status :
Active, not recruiting
First Posted : January 29, 2019
Last Update Posted : April 30, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Endometrial Cancer | Behavioral: Tailored Feedback Messages | Not Applicable |
Objectives:
- To assess if a tailored feedback fitness intervention can increase physical activity in EC survivors from baseline to 12 weeks post-baseline
- To determine the acceptability of the fitness intervention in EC survivors through a completion survey.
- To assess if a tailored feedback message fitness intervention can (1) decrease BMI, (2) reduce waitst to hip (W.H) ratios, (3) improve quality of life (QOL) and (4) improve serum metabolic markers (insulin, glucose and low density lipoprotein (LDL) in EC survivors.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 39 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Single (Investigator) |
Primary Purpose: | Prevention |
Official Title: | The MOVES Trial: MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback |
Actual Study Start Date : | September 28, 2018 |
Actual Primary Completion Date : | December 23, 2019 |
Estimated Study Completion Date : | December 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Tailored Feedback Messages
Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly based on the CHART algorithm (Appendix 1). Participants on the feedback arm will receive 1 message per week during the 3-month study period.
|
Behavioral: Tailored Feedback Messages
Participants randomized to the message arm will begin receiving encouragement and reminder UNC CHART messages to increase physical activity weekly. Participants on the feedback arm will receive 1 message per week during the 3-month study period. |
No Intervention: No Messages
No feedback messages
|
- Change in steps in endometrial cancer survivors during 12 week intervention [ Time Frame: 2 years ]Steps recorded on a fitness tracker at week 1 and week 13

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Be over the age of 18 years
- Have a confirmed diagnosis of endometrial cancer and have completed therapy (surgery, chemotherapy or radiation) within the past 6 months
- Have no current evidence of endometrial cancer
- Have a BMI 25 kg/m2 or greater
- Have approval from their treating physician to engage in moderate-intensity physical activity.
- Have a smart phone with Bluetooth capabilities turned on
- Have access to email
Exclusion Criteria:
- Are currently undergoing treatment for their cancer
- Are unable to read a sample message aloud
- Do not have a computer or smart phone with Bluetooth capabilities
- Are pregnant
- Have a history of angina or palpitations with exertion
- Have a history of uncontrolled pulmonary disease (COPD or asthma)
- Have one or more significant medical conditions that in the physician's judgment preclude participation in the walking intervention.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03820024
United States, North Carolina | |
North Carolina Cancer Hospital | |
Chapel Hill, North Carolina, United States, 27599 |
Principal Investigator: | Leslie Clark, MD | UNC Lineberger Comprehensive Cancer Center |
Responsible Party: | UNC Lineberger Comprehensive Cancer Center |
ClinicalTrials.gov Identifier: | NCT03820024 |
Other Study ID Numbers: |
LCCC 1614 |
First Posted: | January 29, 2019 Key Record Dates |
Last Update Posted: | April 30, 2020 |
Last Verified: | April 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Endometrial Neoplasms Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms |
Neoplasms by Site Neoplasms Uterine Diseases |